Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.

Molecular targeted therapy for anticancer treatment

Open access
Min, Hye-Young, Lee, Ho-Young · 2022 · Experimental & Molecular Medicine

Abstract

Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistance is a major drawback of molecular targeted therapy, and several strategies have been attempted to improve therapeutic efficacy by overcoming such resistance. Herein, we summarize current knowledge regarding several targeted therapeutic agents, including classification, a brief biology of target kinases, mechanisms of action, examples of clinically used targeted therapy, and perspectives for future development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s12276-022-00864-3

Cites

257 of 257 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Timeline for the approval of selected molecular targeted therapeutic agents. The first FDA-approved targeted therapeutic agent for each cellular target (denoted in blankets) is indicated in the timeline.
Fig. 1 Timeline for the approval of selected molecular targeted therapeutic agents. The first FDA-approved targeted therapeutic agent for each cellular target (denoted in blankets) is indicated in the timeline.CC BY · PubMed Central
Fig. 2 Mechanism of the anticancer effect of molecular targeted therapy. a Schematic diagrams of the main protumor signal transduction pathways and their inhibition by molecular targeted therapeutic agents. b, c Schematic diagrams for antibody-dependent cellular cytotoxicity b and trogoptosis c. See the text and relevant references for details.
Fig. 2 Mechanism of the anticancer effect of molecular targeted therapy. a Schematic diagrams of the main protumor signal transduction pathways and their inhibition by molecular targeted therapeutic agents. b, c Schematic diagrams for antibody-dependent cellular cytotoxicity b and trogoptosis c. See the text and relevant references for details.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 257 references

Research works printed but not linked: 1

  1. Tsang, R. Y., Sadeghi, S. & Finn, R. S. Lapatinib, a dual-targeted small molecule inhibitor of EGFR and HER2, in HER2-amplified breast cancer: from bench to bedside. Clin. Med. Insights: Ther. 3, CMT.S3783 (2011).

Cited by

See all 684

Metadata

Authors
Min, H.-Y., & Lee, H.-Y.
Affiliations
Seoul National University (KR)
Corresponding author
Lee, Ho-Young
Venue
Experimental & Molecular Medicine
Published
2022-10-12
Volume
54
Issue
10
Pages
1670-1694
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W4304695118
Cited by
569
References
257
Citations by year
2026: 153 · 2025: 223 · 2024: 151 · 2023: 41 · 2022: 1
FWCI
18.01
Type
journal article
Language
en
Open access
Licence
Locations
  • Experimental & Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
National Research Foundation of Korea (NRF-2016R1A3B1908631)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
targeted therapy, anticancer agents, small-molecule kinase inhibitors, monoclonal antibodies, signal transduction inhibitors, precision medicine, drug resistance, mechanism of action
MeSH terms
Antibodies, Monoclonal, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Neoplasm, Precision Medicine, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular targeted therapy for anticancer treatment. https://app.cochat.ai/papers/10.1038/s12276-022-00864-3
The paper
Min, H.-Y., & Lee, H.-Y. (2022). Molecular targeted therapy for anticancer treatment. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-022-00864-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.